Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2)

Phase 3, randomised, double-blind trial in Focal onset seizure and Focal Onset Epilepsy comparing XEN1101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Proportion of subjects with ≥50% reduction in monthly focal seizure frequency. Started Apr 2023; status: completed.